Follow
Craig Underhill
Craig Underhill
Border Medical Oncology, University of NSW and Latrobe University
Verified email at bordermedonc.com.au
Title
Cited by
Cited by
Year
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, ...
Journal of Clinical Oncology 15 (1), 261-267, 1997
11821997
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …
HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...
The Lancet Oncology 18 (9), 1159-1171, 2017
4052017
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17
SY Brulé, DJ Jonker, CS Karapetis, CJ O’Callaghan, MJ Moore, R Wong, ...
European journal of cancer 51 (11), 1405-1414, 2015
4022015
A review of PARP inhibitors: from bench to bedside
C Underhill, M Toulmonde, H Bonnefoi
Annals of Oncology 22 (2), 268-279, 2011
3142011
Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review
PN Butow, F Phillips, J Schweder, K White, C Underhill, D Goldstein, ...
Supportive Care in Cancer 20, 1-22, 2012
2692012
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
O Kondrashova, M Topp, K Nesic, E Lieschke, GY Ho, MI Harrell, ...
Nature communications 9 (1), 3970, 2018
2632018
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
M Maio, K Lewis, L Demidov, M Mandalà, I Bondarenko, PA Ascierto, ...
The Lancet Oncology 19 (4), 510-520, 2018
2502018
Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial
O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ...
JAMA oncology 6 (9), 1405-1409, 2020
2112020
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
TP Hughes, S Branford, DL White, J Reynolds, R Koelmeyer, JF Seymour, ...
Blood, The Journal of the American Society of Hematology 112 (10), 3965-3973, 2008
2042008
Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised …
D Kotasek, G Steger, W Faught, C Underhill, E Poulsen, AB Colowick, ...
European Journal of Cancer 39 (14), 2026-2034, 2003
1962003
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor–positive metastatic breast cancer: a randomized phase II study
CK Osborne, P Neven, LY Dirix, JR Mackey, J Robert, C Underhill, ...
Clinical Cancer Research 17 (5), 1147-1159, 2011
1952011
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ...
Annals of Oncology 27 (3), 417-423, 2016
1642016
Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers
O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ...
Clinical Cancer Research 26 (17), 4454-4459, 2020
1552020
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ...
PLoS medicine 18 (5), e1003620, 2021
1482021
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
L Mileshkin, JJ Biagi, P Mitchell, C Underhill, A Grigg, R Bell, ...
Blood 102 (1), 69-77, 2003
1482003
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma
MK Gandhi, E Lambley, J Burrows, U Dua, S Elliott, PJ Shaw, HM Prince, ...
Clinical Cancer Research 12 (2), 460-464, 2006
1462006
Prognostic gene expression signature for high-grade serous ovarian cancer
J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ...
Annals of Oncology 31 (9), 1240-1250, 2020
1212020
Mapping oncology services in regional and rural Australia
C Underhill, R Bartel, D Goldstein, H Snodgrass, S Begbie, P Yates, ...
Australian Journal of Rural Health 17 (6), 321-329, 2009
1202009
Treatment of invasive thymoma with single-agent ifosfamide
MS Highley, CR Underhill, FX Parnis, C Karapetis, E Rankin, J Dussek, ...
Journal of clinical oncology 17 (9), 2737-2737, 1999
1181999
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an …
CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ...
The Lancet Oncology 24 (4), 323-334, 2023
1042023
The system can't perform the operation now. Try again later.
Articles 1–20